Annual CFO
-$69.09 M
+$97.48 M+58.52%
December 31, 2023
Summary
- As of February 8, 2025, FOLD annual cash flow from operations is -$69.09 million, with the most recent change of +$97.48 million (+58.52%) on December 31, 2023.
- During the last 3 years, FOLD annual CFO has risen by +$164.20 million (+70.38%).
- FOLD annual CFO is now -554.79% below its all-time high of $15.19 million, reached on December 31, 2007.
Performance
FOLD Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$22.97 M
-$45.66 M-201.23%
September 30, 2024
Summary
- As of February 8, 2025, FOLD quarterly cash flow from operations is -$22.97 million, with the most recent change of -$45.66 million (-201.23%) on September 30, 2024.
- Over the past year, FOLD quarterly CFO has increased by +$15.38 million (+40.10%).
- FOLD quarterly CFO is now -154.16% below its all-time high of $42.41 million, reached on December 31, 2007.
Performance
FOLD Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$26.52 M
+$15.38 M+36.70%
September 30, 2024
Summary
- As of February 8, 2025, FOLD TTM cash flow from operations is -$26.52 million, with the most recent change of +$15.38 million (+36.70%) on September 30, 2024.
- Over the past year, FOLD TTM CFO has increased by +$126.80 million (+82.70%).
- FOLD TTM CFO is now -224.10% below its all-time high of $21.37 million, reached on June 30, 2008.
Performance
FOLD TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
FOLD Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.5% | +40.1% | +82.7% |
| 3 y3 years | +70.4% | +40.1% | +82.7% |
| 5 y5 years | +77.0% | +40.1% | +82.7% |
FOLD Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +65.9% | -201.2% | +71.6% | at high | +86.9% |
| 5 y | 5-year | at high | +72.4% | -201.2% | +78.7% | at high | +90.5% |
| alltime | all time | -554.8% | +77.0% | -154.2% | +82.7% | -224.1% | +92.0% |
Amicus Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$22.97 M(-201.2%) | -$26.52 M(-36.7%) |
| Jun 2024 | - | $22.69 M(-176.4%) | -$41.89 M(-48.1%) |
| Mar 2024 | - | -$29.70 M(-958.7%) | -$80.72 M(+16.8%) |
| Dec 2023 | -$69.09 M(-58.5%) | $3.46 M(-109.0%) | -$69.09 M(-54.9%) |
| Sep 2023 | - | -$38.35 M(+137.7%) | -$153.32 M(+21.1%) |
| Jun 2023 | - | -$16.13 M(-10.7%) | -$126.60 M(+0.2%) |
| Mar 2023 | - | -$18.07 M(-77.6%) | -$126.33 M(-24.2%) |
| Dec 2022 | -$166.57 M(-17.7%) | -$80.77 M(+594.8%) | -$166.57 M(+6.6%) |
| Sep 2022 | - | -$11.63 M(-26.7%) | -$156.32 M(-7.2%) |
| Jun 2022 | - | -$15.86 M(-72.8%) | -$168.39 M(-10.6%) |
| Mar 2022 | - | -$58.31 M(-17.3%) | -$188.45 M(-6.9%) |
| Dec 2021 | -$202.49 M(-13.2%) | -$70.51 M(+197.5%) | -$202.49 M(+11.4%) |
| Sep 2021 | - | -$23.70 M(-34.0%) | -$181.80 M(-9.1%) |
| Jun 2021 | - | -$35.92 M(-50.4%) | -$200.11 M(+1.2%) |
| Mar 2021 | - | -$72.35 M(+45.2%) | -$197.70 M(-15.3%) |
| Dec 2020 | -$233.29 M(-6.8%) | -$49.82 M(+18.6%) | -$233.29 M(-3.3%) |
| Sep 2020 | - | -$42.01 M(+25.3%) | -$241.30 M(-5.3%) |
| Jun 2020 | - | -$33.52 M(-68.9%) | -$254.84 M(-8.9%) |
| Mar 2020 | - | -$107.94 M(+86.6%) | -$279.81 M(+11.7%) |
| Dec 2019 | -$250.42 M(-16.5%) | -$57.83 M(+4.1%) | -$250.42 M(-1.1%) |
| Sep 2019 | - | -$55.55 M(-5.0%) | -$253.26 M(-23.4%) |
| Jun 2019 | - | -$58.48 M(-25.5%) | -$330.47 M(+0.5%) |
| Mar 2019 | - | -$78.55 M(+29.4%) | -$328.98 M(+9.7%) |
| Dec 2018 | -$299.95 M(+40.4%) | -$60.68 M(-54.3%) | -$299.95 M(-4.0%) |
| Sep 2018 | - | -$132.76 M(+132.9%) | -$312.31 M(+36.7%) |
| Jun 2018 | - | -$56.99 M(+15.1%) | -$228.45 M(+7.1%) |
| Mar 2018 | - | -$49.52 M(-32.2%) | -$213.37 M(-0.2%) |
| Dec 2017 | -$213.69 M(+42.3%) | -$73.03 M(+49.3%) | -$213.69 M(+24.1%) |
| Sep 2017 | - | -$48.90 M(+16.7%) | -$172.26 M(+4.9%) |
| Jun 2017 | - | -$41.91 M(-15.9%) | -$164.23 M(+5.9%) |
| Mar 2017 | - | -$49.84 M(+57.7%) | -$155.05 M(+3.3%) |
| Dec 2016 | -$150.15 M(+49.9%) | -$31.60 M(-22.7%) | -$150.15 M(-2.5%) |
| Sep 2016 | - | -$40.88 M(+24.9%) | -$154.06 M(+14.8%) |
| Jun 2016 | - | -$32.73 M(-27.2%) | -$134.20 M(+8.1%) |
| Mar 2016 | - | -$44.94 M(+26.5%) | -$124.10 M(+23.9%) |
| Dec 2015 | -$100.14 M | -$35.51 M(+69.0%) | -$100.14 M(+26.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$21.02 M(-7.2%) | -$79.14 M(+8.0%) |
| Jun 2015 | - | -$22.64 M(+7.9%) | -$73.24 M(+17.3%) |
| Mar 2015 | - | -$20.98 M(+44.6%) | -$62.42 M(+20.8%) |
| Dec 2014 | -$51.67 M(+12.8%) | -$14.51 M(-4.1%) | -$51.67 M(+14.1%) |
| Sep 2014 | - | -$15.12 M(+27.9%) | -$45.28 M(+3.7%) |
| Jun 2014 | - | -$11.82 M(+15.6%) | -$43.67 M(+3.7%) |
| Mar 2014 | - | -$10.22 M(+25.9%) | -$42.11 M(-8.0%) |
| Dec 2013 | -$45.79 M(+35.7%) | -$8.12 M(-39.9%) | -$45.79 M(+1.7%) |
| Sep 2013 | - | -$13.51 M(+31.7%) | -$45.05 M(+16.3%) |
| Jun 2013 | - | -$10.26 M(-26.2%) | -$38.73 M(-2.2%) |
| Mar 2013 | - | -$13.90 M(+88.5%) | -$39.60 M(+17.4%) |
| Dec 2012 | -$33.74 M(-31.7%) | -$7.37 M(+2.4%) | -$33.74 M(-13.2%) |
| Sep 2012 | - | -$7.20 M(-35.3%) | -$38.89 M(-13.0%) |
| Jun 2012 | - | -$11.13 M(+38.5%) | -$44.68 M(+1.2%) |
| Mar 2012 | - | -$8.04 M(-35.8%) | -$44.16 M(-10.7%) |
| Dec 2011 | -$49.42 M(+253.4%) | -$12.52 M(-3.6%) | -$49.42 M(+240.0%) |
| Sep 2011 | - | -$12.99 M(+22.4%) | -$14.54 M(+15.3%) |
| Jun 2011 | - | -$10.61 M(-20.3%) | -$12.61 M(-9.0%) |
| Mar 2011 | - | -$13.31 M(-159.5%) | -$13.86 M(-0.9%) |
| Dec 2010 | -$13.98 M(-67.8%) | $22.36 M(-302.2%) | -$13.98 M(-70.2%) |
| Sep 2010 | - | -$11.06 M(-6.7%) | -$46.94 M(-0.9%) |
| Jun 2010 | - | -$11.86 M(-11.7%) | -$47.35 M(+3.0%) |
| Mar 2010 | - | -$13.43 M(+26.8%) | -$45.95 M(+5.9%) |
| Dec 2009 | -$43.37 M(+17.7%) | -$10.59 M(-7.7%) | -$43.37 M(-7.9%) |
| Sep 2009 | - | -$11.47 M(+9.7%) | -$47.08 M(+8.9%) |
| Jun 2009 | - | -$10.46 M(-3.6%) | -$43.23 M(+6.7%) |
| Mar 2009 | - | -$10.85 M(-24.1%) | -$40.52 M(+9.9%) |
| Dec 2008 | -$36.86 M(-342.6%) | -$14.30 M(+87.5%) | -$36.86 M(-285.7%) |
| Sep 2008 | - | -$7.63 M(-1.5%) | $19.85 M(-7.1%) |
| Jun 2008 | - | -$7.74 M(+7.6%) | $21.37 M(+14.1%) |
| Mar 2008 | - | -$7.20 M(-117.0%) | $18.73 M(+23.3%) |
| Dec 2007 | $15.19 M(-144.8%) | $42.41 M(-794.8%) | $15.19 M(-155.8%) |
| Sep 2007 | - | -$6.10 M(-41.2%) | -$27.22 M(+28.9%) |
| Jun 2007 | - | -$10.38 M(-3.3%) | -$21.12 M(+96.7%) |
| Mar 2007 | - | -$10.74 M | -$10.74 M |
| Dec 2006 | -$33.89 M(+87.0%) | - | - |
| Dec 2005 | -$18.12 M | - | - |
FAQ
- What is Amicus Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Amicus Therapeutics?
- What is Amicus Therapeutics annual CFO year-on-year change?
- What is Amicus Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly CFO year-on-year change?
- What is Amicus Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Amicus Therapeutics?
- What is Amicus Therapeutics TTM CFO year-on-year change?
What is Amicus Therapeutics annual cash flow from operations?
The current annual CFO of FOLD is -$69.09 M
What is the all time high annual CFO for Amicus Therapeutics?
Amicus Therapeutics all-time high annual cash flow from operations is $15.19 M
What is Amicus Therapeutics annual CFO year-on-year change?
Over the past year, FOLD annual cash flow from operations has changed by +$97.48 M (+58.52%)
What is Amicus Therapeutics quarterly cash flow from operations?
The current quarterly CFO of FOLD is -$22.97 M
What is the all time high quarterly CFO for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly cash flow from operations is $42.41 M
What is Amicus Therapeutics quarterly CFO year-on-year change?
Over the past year, FOLD quarterly cash flow from operations has changed by +$15.38 M (+40.10%)
What is Amicus Therapeutics TTM cash flow from operations?
The current TTM CFO of FOLD is -$26.52 M
What is the all time high TTM CFO for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM cash flow from operations is $21.37 M
What is Amicus Therapeutics TTM CFO year-on-year change?
Over the past year, FOLD TTM cash flow from operations has changed by +$126.80 M (+82.70%)